Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 972-976

  Sereno, Denis ^a   Lemesre, Jean Loup ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIMONY TARTRATE; DIMINAZENE ACETURATE; PENTAMIDINE ISETHIONATE; PRIMAQUINE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG SCREENING; DRUG SENSITIVITY; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; MODEL; NONHUMAN; PRIORITY JOURNAL;

EID: 0030902239     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.972     Document Type: Article

References (36)

1. Atkinson, A. J., and J. E. Benett. 1978. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:271-276.
2. Basselin, M., F. Lawrence, and M. Robert-Gero. 1996. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem. J. 315:631-634.
3. Bates, P. A. 1993. Axenic culture of Leishmania amastigotes. Parasitol. Today 9143-146.
4. Bates, P. A., C. D. Robertson, L. Tetley, and G. H. Coombs. 1992. Axenic cultivation and characterization of Leishmania mesicana amastigote-like forms. Parasitology 105:193-202.
5. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev. Infect. Dis. 10:560-586.
6. Berman, J. D., and D. J. Wyler. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142:83-86.
7. Berman, J. D., and J. V. Gallalee. 1985. Semiautomated assessment of in vitro activity of potential antileishmial drugs. Antimicrob. Agents Chemother. 28:723-726.
8. Berman, J. D., D. Waddell, and B. D. Hanson. 1985. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother. 27:916-920.
9. Berman, J. D., J. V. Gallalee, and B. D. Hansen. 1987. Leishmania mexicana uptake of sodium stibogluconate (Pentostam) and pentamidine by parasite and macrophage. Exp. Parasitol. 64:127-131.
10. Berman, J. D., J. V. Gallalee, and J. M. Best. 1987. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta oxydation in Leishmania mexicana amastigotes. Biochem. Pharmacol. 36:197-201.
11. Coombs, G. H., J. A. Craft, and D. T. Hart. 1982. A comparative study of Leishmania mexicana amastigotes and promastigotes. Enzyme activities and subcellular locations. Mol. Biochem. Parasitol. 5:199-211.
12. Gebre-Hiwot, A., G. Tadesse, S. L. Croft, and D. Frommel. 1992. An in vitro model for screening antileishmanial drugs: the human leukemia monocyte cell line. THP-1. Acta Trop. 51:237-245.
13. Goodwin, L. G. 1995. Pentostam® (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg. 89:339-341.
14. Goodwin, L. G., and J. E. Page. 1943. A study of the excretion of organic antimonials using a polarographic procedure. Biochem. J. 22:236-240.
15. Grögl, M., T. N. Thomason, and E. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
16. Haidaris, C. G., and P. F. Bonventre. 1983. Efficacy of combined immunostimulation and chemotherapy in experimental visceral leishmaniaisis. Am. J. Trop. Med. Hyg. 32:286-295.
17. Hassan, H. F., and G. H. Coombs. 1985. Leishmania mexicana, purine metabolizing enzymes of amastigotes and promastigotes. Exp. Parasitol. 59:15-28.
18. Hills, M., C. Hudson, and P. G. Smith. 1986. Global monitoring of the resistance of malarial parasites to drugs: statistical treatment of micro-test data. Working paper 2.8.5. Informal consultation on the epidemiology of drug resistance of malaria parasites, Geneva, Switzerland.
19. Huber, W., and J. C. Koella. 1993. A comparison of three methods of estimating Ec50 in studies of drug resistance of malaria parasites. Acta Trop. 55:257-261.
20. Lamy, L., T. Wonde, and H. Lamy. 1966. Activité de l'amphotéricine B sur Leishmania donovani en multiplication dans des macrophages de souris entretenus in vitro. Bull. Soc. Pathol. Exot. 59:964-968.
21. 20a. Lemesre, J.-L. May 1994. French patent pCT/FR 94/00577.
22. Lemesre, J. L., D. Sereno, S. Daulouéde, B. Veyret, N. Brajon, and P. Vincendeau. Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigote and axenically-grown amastigote forms. Exp. Parasitol., in press.
23. Mattock, N. M., and W. Peters. 1975. The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Ann. Trop. Med. Parasitol. 69:359-371.
24. Mattock, N. M., and W. Peters. 1975. The experimental chemotherapy of leishmaniasis. I. Technique for the study of drug action in tissue culture. Ann. Trop. Med. Parasitol. 69:359-371.
25. Moreira, E. S., R. M. Soares, and M. L. Petrillo-Peixoto. 1995. Glucantime susceptibility of Leishmania promastigotes under variable growth conditions. Parasitol. Res. 81:291-295.
26. Mottram, J. C., and G. H. Coombs. 1985. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol. 59:151-160.
27. Neal, R. A. 1987. Experimental chemotherapy, p. 793-845. In W. Peters and R. Killick-Kendrick (ed.), The leishmaniases in biology and medicine, Vol. II. Academic Press Inc., London, United Kingdom.
28. Neal, R. A., and S. L. Croft. 1984. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
29. Peters, B. S., D. Fish, R. Golden, D. A. Evans, A. D. M. Bryceson, and A. J. Pinching. 1990. Visceral leishmaniasis in HIV infection and AIDS: clinical feature and response to therapy. Q. J. Med. 77:1101-1111.
30. Rainey, P. M., T. W. Spithill, D. McMahon-Pratt, and A. Pan. 1991. Biochemical and molecular characterization of Leishmania pifanoi amastigotes in continuous axenic culture. Mol. Biochem. Parasitol. 49:111-118.
31. Rees, P. H., M. I. Keating, P. A. Kager, and W. T. Hockmeyer. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet ii:226-229.
32. Roberts, W. L., and P. M. Rainey. 1993. Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy. Anal. Biochem. 211:1-6.
33. Roberts, W. L., and P. M. Rainey. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1842-1846.
34. Roberts, W. L., J. D. Berman, and P. M. Rainey. 1995. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39:1234-1239.
35. Sereno, D., and J. L. Lemesre. Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro. Parasitol. Res., in press.
36. Waalkes, T. P., and V. T. Devita. 1970. The determination of pentamidine (4-4′-diaminodinophenoxypentane) in plasma, urine and tissues. J. Lab. Clin. Med. 75:871-878.